Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Biogen Idec Ltd.

Home Clinical Trial Sponsors and OrganizationsBiogen Idec Ltd.

Biogen Idec Ltd.

ACTIVE

United Kingdomwww.biogen.uk.comSubsidiary

Part of Biogen, Inc.

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

145

141 active

Approvals

10

Total approvals

Agencies

1

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 1

46

31.7%

Phase 3

4

2.8%

Trial Status Distribution

Active, not recruiting

141

97.2%

Completed

4

2.8%

Clinical Trials

Trials sponsored by this organization (145)

Anti-TWEAK in lupus nephritis study

Active, not recruiting

Jun 2012300 participants

Long-Term Safety and Efficacy of Recombinant Human Coagulation Factor VIII Fusion Protein (rFVIIIFc)

May 2012194 participants

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Active, not recruiting

Mar 2012856 participants

Comparison of Daclizumab HYP and Avonex® in Multiple Sclerosis

Active, not recruiting

Jan 20121,841 participants

A Randomized, Blinded, Parallel-Group, Phase 2 Study Exploring the Safety, Tolerability, and Efficacy of Multiple Regimens of Natalizumab in Adult Subjects With Relapsing Multiple Sclerosis

Active, not recruiting

Dec 2011300 participants

A-LONG: An Open-label, Multicenter Evaluation of the Safety, Pharmacokinetics, and Efficacy of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in the Prevention and Treatment of Bleeding in Previously Treated Subjects with Severe Hemophilia A. - ND

Active, not recruiting

May 2011180 participants

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Pilot Study to Assess the Efficacy, Safety, and Tolerability of Baminercept in Subjects With Moderate to Severe Ulcerative Colitis

Active, not recruiting

Nov 2010100 participants

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Pilot Study to Assess the Efficacy, Safety, and Tolerability of Baminercept in Subjects With Moderate to Severe Ulcerative Colitis

Active, not recruiting

Oct 2010100 participants

Page 1 of 19

Approvals

Approvals by Agency

EMC

Electronic Medicines Compendium

10

Approvals

Recent Approvals

Qalsody 100 mg Solution for injection

Zurzuvae 30 mg Hard Capsules

Zurzuvae 25mg Hard Capsule

Zurzuvae 20 mg Hard Capsules

Skyclarys 50 mg hard capsules

Plegridy 125 micrograms solution for injection in pre-filled syringe

Plegridy 125 micrograms solution for injection in pre-filled pen

Vumerity 231 mg gastro-resistant hard capsules

Plegridy 63 micrograms solution for injection in pre-filled pen

TYSABRI 300 mg concentrate for solution for infusion

News

No news articles found

On this page

Overview
Clinical Trials145
Approvals10
News

Back to Organizations